Article
Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Dec 2015
Eng Juliana, Woo Kaitlin M, Sima Camelia S, Plodkowski Andrew, Hellmann Matthew D, Chaft Jamie E, Kris Mark G, Arcila Maria E, Ladanyi Marc, Drilon Alexander
Abstract excerpt
INTRODUCTION: In patients with epidermal growth factor receptor (EGFR)-mutant or KRAS-mutant lung adenocarcinomas, the prognostic impact of a concurrent PIK3CA mutation remains unclear. Although preclinical data suggest that sensitivity to EGFR tyrosine kinase inhibition (TKI) is decreased in EGFR-mutant lung cancers also harboring a PIK3CA mutation, this interaction has not been explored clinically. METHODS:...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.